Abingdon Health (ABDX) Share Price, News & Analysis

Company Overview

Abingdon Health Plc engages in the development, manufacture, and distribution of diagnostic devices in the United Kingdom, the United States, Canada, Europe, and internationally. The company provides Abingdon Simply Test, a range of self-tests in the field of fertility, health and well-being, infectious diseases, and drug testing; PCRD and PCRD FLEX, are nucleic acid lateral flow tests, which are used for rapid readouts post isothermal amplification; and 2019-nCoV Antigen Test, a rapid lateral flow test for the qualitative detection of antigens to SARS-CoV-2, as well as plant health tests; and nucleic acid lateral flow immunoassays. It also offers AppDx, a customizable image capturing technology that transforms a smartphone into a self-sufficient and standalone lateral-flow reader; and Salistick, a rapid saliva-based pregnancy test. In addition, the company provides contract manufacturing, nucleic acid lateral flow test customization, and lateral flow development and manufacturing services. Further, it offers regulatory consultancy services for businesses in the diagnostics sector. The company has a strategic collaboration with DeepVerge plc for the development, manufacturing, and commercialization of lateral flow tests; and Vatic Health Limited for the development, manufacturing, and commercialization of infectious disease lateral flow self-tests. Abingdon Health Plc was incorporated in 2008 and is headquartered in York, the United Kingdom.

Key Stats

• Today's Range: 7.75 to 7.75
• 50-Day Range: 7.71 to 10.14
• 52-Week Range: 6.50 to 13
• Volume: 24,884 shs
• Average Volume: 224,260 shs
• Market Capitalization: £14.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ABDX Stock Analysis - Frequently Asked Questions

How have ABDX shares performed this year?

Abingdon Health's stock was trading at GBX 11 at the beginning of the year. Since then, ABDX shares have decreased by 29.5% and is now trading at GBX 7.75.
View the best growth stocks for 2024 here.

How do I buy shares of Abingdon Health?

Shares of ABDX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Abingdon Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Abingdon Health investors own include 4D pharma (DDDD), genedrive (GDR), Novacyt (NCYT), Rolls-Royce Holdings plc (RR.L), Tullow Oil (TLW), Active Energy Group (AEG) and B&M European Value Retail (BME).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: N/A
• Current Symbol: LON:ABDX
• CUSIP: N/A
• CIK: N/A
• Web: www.abingdonhealth.com
• Phone: 44 19 0440 6082
• Fax: N/A
• Employees: 84
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-1,270,000.00
• Net Margins: -20.72%
• Pretax Margin: N/A
• Return on Equity: -48.69%
• Return on Assets: -17.93%

Debt

• Debt-to-Equity Ratio: 46.64
• Current Ratio: 1.95
• Quick Ratio: 1.96

Sales & Book Value

• Annual Sales: £6.13 million
• Price / Sales: 2.40
• Cash Flow: GBX 3.44 per share
• Price / Cash Flow: 2.25
• Book Value: GBX 1 per share
• Price / Book: 7.75

Miscellaneous

• Outstanding Shares: 189,520,000
• Free Float: N/A
• Market Cap: £14.69 million
• Optionable: Not Optionable
• Beta: 0.13